Published in Gastroenterology on June 01, 1997
An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group. CMAJ (2000) 3.45
An evidence-based appraisal of reflux disease management--the Genval Workshop Report. Gut (1999) 3.45
Clinical practice. Gastroesophageal reflux disease. N Engl J Med (2008) 3.30
External validation of a measurement tool to assess systematic reviews (AMSTAR). PLoS One (2007) 2.70
Treatment of gastro-oesophageal reflux disease in adults. BMJ (1998) 1.62
Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. Gut (2004) 1.60
The Indications, Applications, and Risks of Proton Pump Inhibitors. Dtsch Arztebl Int (2016) 1.45
Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia. CMAJ (2002) 1.43
Long term failure of endoscopic gastroplication (EndoCinch). Gut (2005) 1.38
Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol (2004) 1.36
Comparison of clinical characteristics of patients with gastroesophageal reflux disease who failed proton pump inhibitor therapy versus those who fully responded. J Neurogastroenterol Motil (2011) 1.32
NERD: an umbrella term including heterogeneous subpopulations. Nat Rev Gastroenterol Hepatol (2013) 1.20
Proton pump inhibitors for Barrett's oesophagus. Gut (2000) 1.14
Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther (2015) 1.08
Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf (2014) 1.05
Yield of 24-hour esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy. Dig Dis Sci (2008) 1.04
Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther (2015) 1.04
Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J Gastroenterol (2005) 1.03
Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan. J Gastroenterol (2011) 1.01
Acid peptic diseases: pharmacological approach to treatment. Expert Rev Clin Pharmacol (2009) 1.00
Endoscopic full-thickness plication for the treatment of GERD: long-term multicenter results. Surg Endosc (2006) 0.99
Novel approaches to inhibition of gastric acid secretion. Curr Gastroenterol Rep (2010) 0.96
Diagnosis and treatment of gastroesophageal reflux disease. World J Gastrointest Pharmacol Ther (2014) 0.95
Long-term maintenance effect of radiofrequency energy delivery for refractory GERD: a decade later. Surg Endosc (2014) 0.95
Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci (2002) 0.94
Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials. Can J Gastroenterol (2008) 0.93
New and future drug development for gastroesophageal reflux disease. J Neurogastroenterol Motil (2013) 0.93
Interleukin 1B proinflammatory genotypes protect against gastro-oesophageal reflux disease through induction of corpus atrophy. Gut (2005) 0.91
Gastroesophageal reflux disease and sleep disturbances. J Gastroenterol (2012) 0.91
Definitions of reflux disease and its separation from dyspepsia. Gut (2002) 0.90
Paradigm shift in the management of gastroesophageal reflux disease. Ann Surg (2003) 0.90
Optimal treatment of laryngopharyngeal reflux disease. Ther Adv Chronic Dis (2013) 0.90
Short-term treatment of gastroesophageal reflux disease. J Gen Intern Med (2003) 0.89
On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. Dig Dis Sci (2004) 0.89
Roles of cyclooxygenase 2 and microsomal prostaglandin E synthase 1 in rat acid reflux oesophagitis. Gut (2005) 0.89
Gastroparesis associated with gastroesophageal reflux disease and corresponding reflux symptoms may be corrected by radiofrequency ablation of the cardia and esophagogastric junction. Surg Endosc (2008) 0.87
Mosapride as an adjunct to lansoprazole for symptom relief of reflux oesophagitis. Br J Clin Pharmacol (2010) 0.87
Medical or surgical therapy for erosive reflux esophagitis: cost-utility analysis using a Markov model. Ann Surg (2002) 0.86
More severe upper gastrointestinal symptoms associated with non-erosive reflux disease than with erosive gastroesophageal reflux disease during maintenance proton pump inhibitor therapy. J Gastroenterol (2014) 0.86
GERD in the pediatric patient: management considerations. MedGenMed (2004) 0.86
Acid reflux is a poor predictor for severity of erosive reflux esophagitis. Dig Dis Sci (2002) 0.86
Treatment of uncomplicated reflux disease. World J Gastroenterol (2005) 0.85
Overlap of functional dyspepsia and GERD--diagnostic and treatment implications. Nat Rev Gastroenterol Hepatol (2013) 0.84
Asthma and gastroesophageal reflux disease: effect of long-term pantoprazole therapy. World J Gastroenterol (2005) 0.84
Treatment of GORD: Three decades of progress and disappointments. United European Gastroenterol J (2013) 0.84
Long-term follow-up study of the Stretta procedure for the treatment of gastroesophageal reflux disease. Surg Endosc (2004) 0.84
EAES recommendations for the management of gastroesophageal reflux disease. Surg Endosc (2014) 0.84
Management of recurrence of symptoms of gastroesophageal reflux disease: synergistic effect of rebamipide with 15 mg lansoprazole. Dig Dis Sci (2010) 0.83
A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis. Dig Dis Sci (2006) 0.83
Recent effectiveness of proton pump inhibitors for severe reflux esophagitis: the first multicenter prospective study in Japan. J Clin Biochem Nutr (2015) 0.83
Unmet Needs in the Treatment of Gastroesophageal Reflux Disease. J Neurogastroenterol Motil (2015) 0.82
Gastroesophageal reflux disease. J Gastroenterol (2010) 0.82
Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy. World J Gastroenterol (2011) 0.81
Changes in GERD symptom scores correlate with improvement in esophageal acid exposure after the Stretta procedure. Surg Endosc (2004) 0.81
Long-term management of gastroesophageal reflux disease with pantoprazole. Ther Clin Risk Manag (2007) 0.81
Current pharmacological management of gastroesophageal reflux disease. Gastroenterol Res Pract (2013) 0.80
Endoscopic full-thickness plication for the treatment of GERD: Five-year long-term multicenter results. Surg Endosc (2007) 0.80
Gastroesophageal reflux and Helicobacter pylori: a review. World J Gastroenterol (2000) 0.80
pH, healing rate, and symptom relief in patients with GERD. Yale J Biol Med (2000) 0.80
Surgery for gastroesophageal reflux disease: esophageal impedance to progress? Clin Gastroenterol Hepatol (2009) 0.80
Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol (2016) 0.79
Factors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease: a multicenter prospective observational study. J Gastroenterol (2015) 0.79
Eosinophilic esophagitis in patients with typical gastroesophageal reflux disease symptoms refractory to proton pump inhibitor. Clinics (Sao Paulo) (2011) 0.79
Recent advances in noncardiac chest pain in Korea. Gut Liver (2012) 0.79
Impedance-pH monitoring in proton pump inhibitor resistant patients: ready for clinical application? Gut (2006) 0.78
Once-daily omeprazole/sodium bicarbonate heals severe refractory reflux esophagitis with morning or nighttime dosing. Dig Dis Sci (2014) 0.78
Management of laryngopharyngeal reflux with proton pump inhibitors. Ther Clin Risk Manag (2008) 0.78
Community-acquired pneumonia and acid-suppressive drugs: position statement. Can J Gastroenterol (2006) 0.78
The effect of gastroesophageal flap valve appearance on the management of patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci (2008) 0.77
Positive predictors for gastroesophageal reflux disease and the therapeutic response to proton-pump inhibitors. World J Gastroenterol (2014) 0.77
Proton pump inhibitor step-down therapy for GERD: a multi-center study in Japan. World J Gastroenterol (2011) 0.77
Acid reflux directly causes sleep disturbances in rat with chronic esophagitis. PLoS One (2014) 0.77
A pilot study of efficacy and safety of continuous intravenous infusion of pantoprazole in the treatment of severe erosive esophagitis. Dig Dis Sci (2008) 0.77
Prospective, Randomized Ex Vivo Trial to Assess the Ideal Stapling Site for Endoscopic Fundoplication with Medigus Ultrasonic Surgical Endostapler. Gastroenterol Res Pract (2016) 0.76
Drugs, bugs, and esophageal pH profiles. Yale J Biol Med (2000) 0.76
Gastrin stimulates a cholecystokinin-2-receptor-expressing cardia progenitor cell and promotes progression of Barrett's-like esophagus. Oncotarget (2017) 0.76
Management of reflux disease. Gut (2002) 0.76
Combination of angiotensin II receptor blockers promotes proton pump inhibitor-based healing of reflux esophagitis. J Gastroenterol (2011) 0.76
Long-term follow-up results of endoscopic treatment of gastroesophageal reflux disease with the MUSE™ endoscopic stapling device. Surg Endosc (2015) 0.76
Patient satisfaction with medication for gastroesophageal reflux disease: a systematic review. Can J Gastroenterol (2012) 0.76
Persistent gastro-oesophageal reflux symptoms despite proton pump inhibitor therapy. Singapore Med J (2016) 0.76
25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver (2016) 0.76
Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: focus on delayed-release esomeprazole. Ther Clin Risk Manag (2010) 0.75
Treatment of gastro-oesophageal reflux disease in adults. Efficacy of surgery needs to be compared with that of proton pump inhibitors. BMJ (1999) 0.75
Reflux control is important in the management of Barrett's Esophagus: results from a retrospective 1,830 patient cohort. Surg Endosc (2015) 0.75
Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia. Biomed Rep (2016) 0.75
Gastroesophageal reflux in critically ill children: a review. ISRN Gastroenterol (2013) 0.75
Digestive system disorders: gastroesophageal reflux disease. West J Med (2000) 0.75
The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease. Therap Adv Gastroenterol (2017) 0.75
Factors associated with complicated erosive esophagitis: A Japanese multicenter, prospective, cross-sectional study. World J Gastroenterol (2017) 0.75
Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy. World J Gastroenterol (2017) 0.75
Medical therapy of gastroesophageal reflux disease in secondary and tertiary care settings. Yale J Biol Med (2000) 0.75
Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole. Clin Exp Gastroenterol (2016) 0.75
Bravo pH Testing On and Off Treatment With Immediate-Release Omeprazole: A Review of Findings Presented at the 71st Annual Scientific Meeting of the American College of Gastroenterology October 20-25, 2006 Las Vegas, Nev. Gastroenterol Hepatol (N Y) (2007) 0.75
Prospective Study of Gastroesophageal Reflux, Use of Proton Pump Inhibitors and H2-Receptor Antagonists, and Risk of Hearing Loss. Ear Hear (2016) 0.75
Management of Asymptomatic Erosive Esophagitis: An E-Mail Survey of Physician's Opinions. Gut Liver (2013) 0.75
Supplementation of Los Angeles classification with esophageal mucosa index of hemoglobin can predict the treatment response of erosive reflux esophagitis. Surg Endosc (2011) 0.75
Anopheles funestus resistant to pyrethroid insecticides in South Africa. Med Vet Entomol (2000) 7.40
A cocktail polymerase chain reaction assay to identify members of the Anopheles funestus (Diptera: Culicidae) group. Am J Trop Med Hyg (2002) 5.18
Single nocturnal dose of an H2 receptor antagonist for the treatment of duodenal ulcer. Gut (1983) 4.47
Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology (1998) 4.13
Bioassay and biochemical analyses of insecticide resistance in southern African Anopheles funestus (Diptera: Culicidae). Bull Entomol Res (2001) 3.34
Helicobacter pylori: new developments and treatments. CMAJ (1997) 2.77
Variation in the N-terminal sequence of heavy chains of immunoglobulin G from rabbits of different allotype. Biochem J (1969) 2.59
Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology (1990) 2.49
Expression of interleukin 8 and CD54 by human gastric epithelium after Helicobacter pylori infection in vitro. Gastroenterology (1995) 2.48
Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs. Gut (1987) 2.40
Recommendations for standardization and phenotype definitions in genetic studies of osteoarthritis: the TREAT-OA consortium. Osteoarthritis Cartilage (2010) 2.39
Anopheles arabiensis and An. quadriannulatus resistance to DDT in South Africa. Med Vet Entomol (2003) 2.29
Biological activities of lavender essential oil. Phytother Res (2002) 2.27
Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol (1992) 2.20
Honey: a potent agent for wound healing? J Wound Ostomy Continence Nurs (2002) 2.18
Relationship between gastric secretion and infection. Gut (1987) 2.09
Colonoscopy for unexplained rectal bleeding. Br Med J (1978) 2.08
The regulatory proteins of the myofibril. Separation and biological activity of the components of inhibitory-factor preparations. Biochem J (1972) 2.06
Intragastric acidity, bacteria, nitrite, and N-nitroso compounds before, during, and after cimetidine treatment. Lancet (1982) 2.05
Accurate flow cytometric membrane potential measurement in bacteria using diethyloxacarbocyanine and a ratiometric technique. Cytometry (1999) 1.96
Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion (1992) 1.95
Access to specialist gastroenterology care in Canada: the Practice Audit in Gastroenterology (PAGE) Wait Times Program. Can J Gastroenterol (2008) 1.94
The immunological activity of some of the chymotryptic peptides of sperm-whale myoglobin. Biochem J (1965) 1.94
Allotypically related sequences in the Fd fragment of rabbit immunoglobulin heavy chains. Biochem J (1971) 1.90
Access to specialist gastroenterology care in Canada: comparison of wait times and consensus targets. Can J Gastroenterol (2008) 1.89
24-hour intragastric acidity and nocturnal acid secretion in patients with duodenal ulcer during oral administration of cimetidine and atropine. Gut (1977) 1.87
The N-terminal sequence of the heavy chain of rabbit immunoglobulin IgG. Biochem J (1966) 1.85
The relationship between biological activity and primary structure of troponin I from white skeletal muscle of the rabbit. Biochem J (1976) 1.84
Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis (2011) 1.80
Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol (1998) 1.78
Multiparameter flow cytometric analysis of antibiotic effects on membrane potential, membrane permeability, and bacterial counts of Staphylococcus aureus and Micrococcus luteus. Antimicrob Agents Chemother (2000) 1.75
Insecticide susceptibility and vector status of natural populations of Anopheles arabiensis from Sudan. Trans R Soc Trop Med Hyg (2007) 1.74
What role does Helicobacter pylori play in dyspepsia and nonulcer dyspepsia? Arguments for and against H. pylori being associated with dyspeptic symptoms. Gastroenterology (1997) 1.72
The preparation and properties of the components of troponin B. Biochim Biophys Acta (1974) 1.58
The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. Aliment Pharmacol Ther (1999) 1.57
The effect of acupuncture on gastrointestinal function and disorders. Am J Gastroenterol (1992) 1.56
A cytological technique for the study of Anopheles gambiae complex. Parassitologia (1974) 1.53
Insights into the genetic architecture of osteoarthritis from stage 1 of the arcOGEN study. Ann Rheum Dis (2010) 1.53
Healing of gastric ulcer during treatment with cimetidine. Lancet (1976) 1.52
Comparison of amino acid sequence of troponin I from different striated muscles. Nature (1978) 1.52
Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut (1992) 1.50
Comparison of twice-daily ranitidine with standard cimetidine treatment of duodenal ulcer. Gut (1981) 1.50
Malaria infection potential of anopheline mosquitoes sampled by light trapping indoors in coastal Tanzanian villages. Med Vet Entomol (1995) 1.47
The phosphorylation sites of troponin I from white skeletal muscle of the rabbit. FEBS Lett (1974) 1.47
Epidemic hypochlorhydria. Br Med J (Clin Res Ed) (1985) 1.47
Adding once-daily omeprazole 20 mg to metronidazole/amoxicillin treatment for Helicobacter pylori gastritis: a randomized, double-blind trial showing the importance of metronidazole resistance. Am J Gastroenterol (1998) 1.47
Rectal bleeding. Clin Gastroenterol (1978) 1.47
Resistance of the malaria vector Anopheles gambiae s.s. to pyrethroid insecticides, in south-western Nigeria. Ann Trop Med Parasitol (2002) 1.44
Meta-analysis: incidence of endoscopic gastric and duodenal ulcers in placebo arms of randomized placebo-controlled NSAID trials. Aliment Pharmacol Ther (2009) 1.44
Insecticide resistance in the malarial mosquito Anopheles arabiensis and association with the kdr mutation. Med Vet Entomol (2007) 1.43
Mitigating climate change: the role of domestic livestock. Animal (2010) 1.41
Calibration of pre-cut iridium-192 wires for low dose rate interstitial brachytherapy using a Farmer-type ionization chamber. Br J Radiol (2000) 1.40
Colonoscopy in the management of colon polyps. Br J Surg (1974) 1.39
Fully automatic segmentation of the proximal femur using random forest regression voting. IEEE Trans Med Imaging (2013) 1.39
Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology (2000) 1.39
Nocturnal doses of H2 receptor antagonists for duodenal ulcer. Lancet (1985) 1.37
The chemical structure of the heavy chains of rabbit and human immunoglobulin G (IgG). Proc R Soc Lond B Biol Sci (1966) 1.36
Insecticide resistance in malaria vector mosquitoes in a gold mining town in Ghana and implications for malaria control. Bull Soc Pathol Exot (2006) 1.33
A Canadian physician survey of dyspepsia management. Can J Gastroenterol (1998) 1.30
Peppermint oil to reduce colonic spasm during endoscopy. Lancet (1982) 1.29
The role of four anopheline species (Diptera: Culicidae) in malaria transmission in coastal Tanzania. Trans R Soc Trop Med Hyg (1998) 1.28
Can severity of symptoms be used as an outcome measure in trials of non-ulcer dyspepsia and Helicobacter pylori associated gastritis? J Clin Epidemiol (1993) 1.27
Treatment after failure: the problem of "non-responders". Gut (1999) 1.22
High-performance liquid chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasma. J Chromatogr B Biomed Sci Appl (1997) 1.21
The amino acid sequence of troponin I from rabbit skeletal muscle. Biochem J (1975) 1.21
Diagnosis and management of non-erosive reflux disease--the Vevey NERD Consensus Group. Digestion (2009) 1.19
Effect of immunologic reactions on rat intestinal epithelium. Correlation of increased permeability to chromium 51-labeled ethylenediaminetetraacetic acid and ovalbumin during acute inflammation and anaphylaxis. Gastroenterology (1988) 1.19
Reversibility of increased intestinal permeability to 51Cr-EDTA in patients with gastrointestinal inflammatory diseases. Am J Gastroenterol (1987) 1.18
Malaria vector composition and insecticide susceptibility status in Guinea Conakry, West Africa. Med Vet Entomol (2009) 1.18
Accuracy and value of the Hemoccult test in symptomatic patients. Br Med J (Clin Res Ed) (1983) 1.17
Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum Mol Genet (2000) 1.17
Dynamics of the malaria-vector populations in coastal Lagos, south-western Nigeria. Ann Trop Med Parasitol (2002) 1.16
Pharmacokinetics and pharmacodynamics of treatments for peptic ulcer disease in the elderly. Am J Gastroenterol (1988) 1.16
Aedes albopictus in Africa? First records of live specimens in imported tires in Cape Town. J Am Mosq Control Assoc (1991) 1.14
Troponin C from rabbit slow skeletal and cardiac muscle is the product of a single gene. Eur J Biochem (1980) 1.14
Detection of hybrids in natural populations of the Anopheles gambiae complex by the rDNA-based, PCR method. Ann Trop Med Parasitol (1997) 1.14
Position of the fovea centralis with respect to the optic nerve head. Optom Vis Sci (1992) 1.13
The amino acid sequence of rabbit cardiac troponin I. Biochem J (1976) 1.12
Effect of acupuncture on gastric acid secretion in healthy male volunteers. Dig Dis Sci (1992) 1.12
Differentiation antigens identify subpopulations of rabbit T and B lymphocytes. Definition by flow cytometry. J Exp Med (1983) 1.11
Gastric secretory studies in humans with impromidine (SK&F 92676)--a specific histamine H2 receptor agonist. Gastroenterology (1980) 1.11
Biting pattern and host-seeking behavior of Anopheles arabiensis (Diptera: Culicidae) in northeastern South Africa. J Med Entomol (1994) 1.11
pH and Hp--gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism. Am J Gastroenterol (1993) 1.10
Small bowel and colonic permeability to 51Cr-EDTA in patients with active inflammatory bowel disease. Clin Invest Med (1988) 1.10
Single-strand conformation polymorphism analysis for identification of four members of the Anopheles funestus (Diptera: Culicidae) group. J Med Entomol (1999) 1.09
The crossing and chromosome characteristics of a new, sixth species in the Anopheles gambiae complex. Parassitologia (1974) 1.09
Commentary: independent risk factors for recurrent neoplasia after endoscopic resection of early gastric cancer. Aliment Pharmacol Ther (2014) 1.08
Angiodysplasia of the colon. Experience of 26 cases. Lancet (1982) 1.07
Urinary catheter tamponade to control intra-operative bleeding from the superior gluteal artery: a case report. J Bone Joint Surg Br (2007) 1.07
The in vivo and in vitro effects of antibodies against rabbit beta 2-integrins. J Immunol (1994) 1.05
Alteration of H2 receptor sensitivity in duodenal ulcer patients after maintenance treatment with an H2 receptor antagonist. Gut (1988) 1.05
Diagnostic approach to evaluating the cause of a positive fecal occult blood test. CA Cancer J Clin (1984) 1.04
Alpha-chains of immunoglobulin A from rabbits of different allotype: composition and N-terminal sequence. Nature (1969) 1.04
Monoclonal antibodies recognizing the N- and C-terminal regions of talin disrupt actin stress fibers when microinjected into human fibroblasts. Cell Motil Cytoskeleton (1997) 1.04
The amino acid sequence of troponin C from chicken skeletal muscle. FEBS Lett (1976) 1.03